151 related articles for article (PubMed ID: 37395368)
1. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
Yamasaki F; Kanahara N; Nakata Y; Koyoshi S; Yanagisawa Y; Saito T; Oiwa T; Kogure M; Sasaki T; Yoshida T; Kimura H; Iyo M
J Psychopharmacol; 2023 Oct; 37(10):992-1002. PubMed ID: 37395368
[TBL] [Abstract][Full Text] [Related]
2. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
Baumann P; Bauknecht P; Kuzin M; Schoretsanitis G
Int J Psychiatry Clin Pract; 2023 Nov; 27(4):367-384. PubMed ID: 37428441
[TBL] [Abstract][Full Text] [Related]
3. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
[TBL] [Abstract][Full Text] [Related]
5. Case series on aripiprazole and dopamine supersensitivity psychosis.
Russell G; Reinfeld S; Kam O; Lee G; Weiss M; Koola MM
Int Clin Psychopharmacol; 2022 May; 37(3):122-128. PubMed ID: 35143441
[TBL] [Abstract][Full Text] [Related]
6. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
7. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
[TBL] [Abstract][Full Text] [Related]
8. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
Simon N; Azorin JM
Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
[TBL] [Abstract][Full Text] [Related]
9. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J; Castle D; Keks NA
Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
11. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
[TBL] [Abstract][Full Text] [Related]
12. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
13. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
15. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
16. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P
CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
[TBL] [Abstract][Full Text] [Related]
17. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
Kogure M; Kanahara N; Kimura M; Hanaoka S; Hirano H; Iyo M
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):357-364. PubMed ID: 35727084
[TBL] [Abstract][Full Text] [Related]
19. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
20. Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia.
Masumo Y; Kanahara N; Kogure M; Yamasaki F; Nakata Y; Iyo M
Int Clin Psychopharmacol; 2023 Mar; 38(2):102-109. PubMed ID: 36719338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
